Shangce Du
Overview
Explore the profile of Shangce Du including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
299
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cao K, Li M, Miao J, Lu X, Kang X, Zhu H, et al.
Am J Transl Res
. 2025 Jan;
16(12):8083-8086.
PMID: 39822537
[This corrects the article on p. 274 in vol. 10, PMID: 29423012.].
2.
Yang C, Geng H, Yang X, Ji S, Liu Z, Feng H, et al.
Cancer Cell
. 2024 Nov;
42(12):2064-2081.e19.
PMID: 39515328
Tumor-initiating cells (TICs) possess the ability to evade anti-tumor immunity, potentially explaining many failures of cancer immunotherapy. Here, we identify CD49f as a prominent marker for discerning TICs in hepatocellular...
3.
Miao B, Hu Z, Mezzadra R, Hoeijmakers L, Fauster A, Du S, et al.
Cancer Cell
. 2023 Sep;
41(10):1817-1828.e9.
PMID: 37683639
The dysregulated expression of immune checkpoint molecules enables cancer cells to evade immune destruction. While blockade of inhibitory immune checkpoints like PD-L1 forms the basis of current cancer immunotherapies, a...
4.
Xu E, Xia X, Jiang C, Li Z, Yang Z, Zheng C, et al.
Front Cell Dev Biol
. 2022 Mar;
10:841792.
PMID: 35281102
[This corrects the article DOI: 10.3389/fcell.2020.591239.].
5.
Du S, Yang Z, Lu X, Yousuf S, Zhao M, Li W, et al.
Oncogene
. 2022 Jan;
41(9):1384-1385.
PMID: 35046535
No abstract available.
6.
Li Y, Yang C, Liu Z, Du S, Can S, Zhang H, et al.
Mol Cancer
. 2022 Jan;
21(1):2.
PMID: 34980132
Background: In recent years, the application of functional genetic immuno-oncology screens has showcased the striking ability to identify potential regulators engaged in tumor-immune interactions. Although these screens have yielded substantial...
7.
Du S, Yang Z, Lu X, Yousuf S, Zhao M, Li W, et al.
Oncogene
. 2021 Aug;
40(38):5764-5779.
PMID: 34341514
Anoikis is a type of programmed cell death induced by loss of anchorage to the extracellular matrix (ECM). Anoikis resistance (AR) is crucial for the survival of metastatic cancer cells...
8.
Wang X, Xia X, Xu E, Yang Z, Shen X, Du S, et al.
Front Cell Dev Biol
. 2021 Feb;
8:592919.
PMID: 33553141
Signet ring cell gastric carcinoma (SRCGC) is a poorly differentiated malignancy, and can be highly dangerous in the progression stage. There is a higher male to female ratio among patients...
9.
Xu E, Xia X, Jiang C, Li Z, Yang Z, Zheng C, et al.
Front Cell Dev Biol
. 2021 Jan;
8:591239.
PMID: 33425895
G protein coupled estrogen receptor (GPER1) is a membrane estrogen receptor, belonging to the seven-transmembrane G protein-coupled receptors family, and has important biological functions in cancer. However, the functional role...
10.
OSI-027 Alleviates Oxaliplatin Chemoresistance in Gastric Cancer Cells by Suppressing P-gp Induction
Xu E, Zhu H, Wang F, Miao J, Du S, Zheng C, et al.
Curr Mol Med
. 2020 Nov;
21(10):922-930.
PMID: 33222668
Gastric cancer is one of the most common malignancies worldwide and the third leading cause of cancer-related death. In the present study, we investigated the potential activity of OSI-027, a...